Literature DB >> 16914135

Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice.

Tsugunobu Andoh1, Yasushi Kuraishi.   

Abstract

Anti-pruritic effects of the antihistamine bepotastine besilate were studied in mice. Bepotastine besilate (10 mg/kg) inhibited scratching induced by an intradermal injection of histamine (100 nmol/site), but not serotonin (100 nmol/site). Bepotastine besilate (1-10 mg/kg, oral) dose-dependently suppressed scratching induced by substance P (100 nmol/site) and leukotriene B(4) (0.03 nmol/site). An intradermal injection of substance P (100 nmol/site) increased the cutaneous concentration of leukotriene B(4), which was not affected by bepotastine besilate (10 mg/kg, oral). Leukotriene B(4) increased Ca(2+) concentration in cultured neutrophils, which was suppressed by bepotastine besilate (1-100 microM). Leukotriene B(4) increased Ca(2+) concentration in cultured dorsal root ganglion neurons, which was also suppressed by bepotastine besilate (100 microM). The results suggest that the inhibition of the actions of leukotriene B(4) as well as histamine is involved in the anti-pruritic effect of bepotastine besilate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914135     DOI: 10.1016/j.ejphar.2006.07.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Oral bepotastine: in allergic disorders.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

2.  Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%.

Authors:  Mark T Bergmann; Jon I Williams; Paul J Gomes
Journal:  Clin Ophthalmol       Date:  2014-08-13

3.  Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis.

Authors:  Norie Aizawa; Yozo Ishiuji; Mitsutoshi Tominaga; Sanae Sakata; Nobuaki Takahashi; Koichi Yanaba; Yoshinori Umezawa; Akihiko Asahina; Utako Kimura; Yasushi Suga; Kenji Takamori; Hidemi Nakagawa
Journal:  J Immunol Res       Date:  2019-01-21       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.